Jose Mauricio Mota

Jose Mauricio Mota

Auto-generated profile, based on publicly available information

Jose Mauricio Mota

Instituto do Câncer do Estado de São Paulo, University of São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2017 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
SPSachin Pai
Sachin Pai
BCBenedito A. Carneiro
Benedito A. Carneiro
JMJose Mauricio Mota
Jose Mauricio Mota
RCRicardo L. B. Costa
Ricardo L. B. Costa
CLCaio Abner Leite
Caio Abner Leite
FGFrancis Giles
Francis Giles
Wnt/β-catenin signaling, a highly conserved pathway through evolution, regulates key cellular functions including proliferation, differentiation, migration, genetic stability, apoptosis, and stem cell renewal. The Wnt pathway mediates biological processes by a canonical or noncanonical pathway, depending on the involvement of β-catenin in signal transduction. β-catenin is a core component of the cadherin protein complex, whose stabilization is essential for the activation of Wnt/β-catenin signaling. As multiple aberrations in this pathway occur in numerous cancers, WNT-directed therapy represents an area of significant developmental therapeutics focus. The recently described role of Wnt/β-catenin pathway in regulating immune cell infiltration of the tumor microenvironment renewed the interest, given its potential impact on responses to immunotherapy treatments. This article summarizes the role of Wnt/β-catenin pathway in cancer and ongoing therapeutic strategies involving this pathway.

5 February 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PCPaula Giselle Czaikoski
Paula Giselle Czaikoski
JMJosé Maurício Segundo Correia Mota
José Maurício Segundo Correia Mota
DNDaniele Carvalho Nascimento
Daniele Carvalho Nascimento
FSFabiane Sônego
Fabiane Sônego
FCFernanda Vargas e Silva Castanheira
Fernanda Vargas e Silva Castanheira
FCFernando Queiróz Cunha
Fernando Queiróz Cunha
Organ dysfunction is a major concern in sepsis pathophysiology and contributes to its high mortality rate. Neutrophil extracellular traps (NETs) have been implicated in endothelial damage and take part in the pathogenesis of organ dysfunction in several conditions. NETs also have an important role in counteracting invading microorganisms during infection. The aim of this study was to evaluate systemic NETs formation, their participation in host bacterial clearance and their contribution to organ dysfunction in sepsis. C57Bl/6 mice were subjected to endotoxic shock or a polymicrobial sepsis model induced by cecal ligation and puncture (CLP). The involvement of cf-DNA/NETs in the physiopathology of sepsis was evaluated through NETs degradation by rhDNase. This treatment was also associated with a broad-spectrum antibiotic treatment (ertapenem) in mice after CLP. CLP or endotoxin administration induced a significant increase in the serum concentrations of NETs. The increase in CLP-induced NETs was sustained over a period of 3 to 24 h after surgery in mice and was not inhibited by the antibiotic treatment. Systemic rhDNase treatment reduced serum NETs and increased the bacterial load in non-antibiotic-treated septic mice. rhDNase plus antibiotics attenuated sepsis-induced organ damage and improved the survival rate. The correlation between the presence of NETs in peripheral blood and organ dysfunction was evaluated in 31 septic patients. Higher cf-DNA concentrations were detected in septic patients in comparison with healthy controls, and levels were correlated with sepsis severity and organ dysfunction. In conclusion, cf-DNA/NETs are formed during sepsis and are associated with sepsis severity. In the experimental setting, the degradation of NETs by rhDNase attenuates organ damage only when combined with antibiotics, confirming that NETs take part in sepsis pathogenesis. Altogether, our results suggest that NETs are important for host bacterial control and are relevant actors in the pathogenesis of sepsis.

15 October 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CWCarlos W. Wanderley
Carlos W. Wanderley
DCDavid F. Colón
David F. Colón
JLJoao Paulo Mesquita Luiz
Joao Paulo Mesquita Luiz
FOFrancisco F. Oliveira
Francisco F. Oliveira
PVPaula R. Viacava
Paula R. Viacava
FCFernando Q. Cunha
Fernando Q. Cunha
Paclitaxel is an antineoplastic agent widely used to treat several solid tumor types. The primary mechanism of action of paclitaxel is based on microtubule stabilization inducing cell-cycle arrest. Here, we use several tumor models to show that paclitaxel not only induces tumor cell-cycle arrest, but also promotes antitumor immunity. In vitro, paclitaxel reprogrammed M2-polarized macrophages to the M1-like phenotype in a TLR4-dependent manner, similarly to LPS. Paclitaxel also modulated the tumor-associated macrophage (TAM) profile in mouse models of breast and melanoma tumors; gene expression analysis showed that paclitaxel altered the M2-like signature of TAMs toward an M1-like profile. In mice selectively lacking TLR4 on myeloid cells, for example, macrophages (LysM-Cre+/−/TLR4fl/fl), the antitumor effect of paclitaxel was attenuated. Gene expression analysis of tumor samples from patients with ovarian cancer before and after treatment with paclitaxel detected an enrichment of genes linked to the M1 macrophage activation profile (IFNγ-stimulated macrophages). These findings indicate that paclitaxel skews TAMs toward an immunocompetent profile via TLR4, which might contribute to the antitumor effect of paclitaxel and provide a rationale for new combination regimens comprising paclitaxel and immunotherapies as an anticancer treatment. Significance: This study provides new evidence that the antitumor effect of paclitaxel occurs in part via reactivation of the immune response against cancer, guiding tumor-associated macrophages toward the M1-like antitumor phenotype. Graphical http://cancerres.aacrjournals.org/content/canres/78/20/5891/F1.large.jpg. Cancer Res; 78(20); 5891–900. ©2018 AACR. See related commentary by Garassino et al., p. 5729

8 April 2017 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
LCLouise C. Connell
Louise C. Connell
JMJosé Mauricio Mota
José Mauricio Mota
MBMaria Ignez Braghiroli
Maria Ignez Braghiroli
PHPaulo M. Hoff
Paulo M. Hoff

2 September 2016 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
RRRonaldo A. Ribeiro
Ronaldo A. Ribeiro
CWCarlos W. S. Wanderley
Carlos W. S. Wanderley
DWDeysi V. T. Wong
Deysi V. T. Wong
JMJosé Maurício S. C. Mota
José Maurício S. C. Mota
CLCaio A. V. G. Leite
Caio A. V. G. Leite
Roberto Lima-JúniorRoberto Lima-Júnior
Roberto Lima-Júnior

7 March 2008 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
PSPedro Paulo da Silva Soares
Pedro Paulo da Silva Soares
JMJosé Maurício S. C. Mota
José Maurício S. C. Mota
AGAntoniella S. Gomes
Antoniella S. Gomes
RORicardo B. Oliveira
Ricardo B. Oliveira
AAAna Maria S. Assreuy
Ana Maria S. Assreuy
MSMarcellus H. L. P. Souza
Marcellus H. L. P. Souza